Progeria: a paradigm for translational medicine.
Rare diseases are powerful windows into biological processes and can serve as models for the development of therapeutic strategies. The progress made on the premature aging disorder Progeria is a shining example of the impact that studies of rare diseases can have.
Department of Anesthesia, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA; Department of Pediatrics, Hasbro Children's Hospital and Warren Alpert Medical School of Brown University, Providence, RI 02912, USA. Electronic address: leslie_gordon@brown.edu.
Leslie B
LB
Gordon
Division of Biology and Medicine, Brown University, Providence, RI 02912, USA.
Frank G
FG
Rothman
Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología (IUOPA), Universidad de Oviedo, 33006 Oviedo, Spain.
Carlos
C
López-Otín
National Cancer Institute, NIH, Bethesda, MD 20892, USA. Electronic address: mistelit@mail.nih.gov.
Tom
T
Misteli
D000375:Aging / Q000235:genetics / Q000473:pathology; D002648:Child; D051231:Farnesyltranstransferase / Q000037:antagonists & inhibitors; D006801:Humans; D034904:Lamin Type A; D009687:Nuclear Proteins / Q000378:metabolism; D011371:Progeria / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000503:physiopathology*; D011498:Protein Precursors / Q000378:metabolism; D057170:Translational Research, Biomedical
D034904:Lamin Type A; D009687:Nuclear Proteins; D011498:Protein Precursors; C090764:prelamin A; D051231:Farnesyltranstransferase